THE EFFECTIVENESS OF CLOPIDOGREL AS AN ANTITHROMBOTIC COMPARED TO TICLOPIDINE AND ASPIRIN (META-ANALYSIS)
Abstract: Clopidogrel, an
antithrombotic drug, has been proven by FDA as Plavix® was initially used for
the prevention of vascular occlusive that cause of myocardial infarction,
stroke, and vascular death in patients with atherosclerosis and then it is used
to treat Acute Coronary Syndrome (ACS). Aim of the study is to compare the
effectiveness of Clopidogrel to aspirin and ticlopidine by meta-analysis of
CLASSICS (The Clopidogrel Aspirin Stent International Cooperative Study), MATCH
trial dan CAPRIE trial. Results of the study show that the effectiveness of
Clopidogrel is significantly higher, however the risk of ischemic and bleeding
is lower than aspirin and ticlopidine. Cost-effectiveness of Clopidogrel in
avoiding secondary stroke in one episode is approximately US $ 33,000, and
aspirin is only US $ 1400. In Indonesia
the price of Clopidogrel is ranged from
US $1.5 to US $3 each tablet, while the price of aspirin ranged from US $
0.35 to US $ 0.72. However, in Indonesia
Clopidogrel is now in the list of National Formulary, this fact might have
contributed to the increasing use of Clopidogrel, which has reached around 1000
tablets per day in each hospital while aspirin has reached almost 1500 tablets per day.
Keywords: antithrombotic;
aspirin; antiplatelet; Clopidogrel; ticlopidine
Penulis: Titien Siwi Hartayu,
Dewi Setyaningsih
Kode Jurnal: jpfarmasidd170445
